Investors are drawn to unprofitable companies due to growth potential. Analyzing VYNE Therapeutics' cash burn and runway, it is crucial to monitor its cash reserves and revenue growth for investment decisions. Despite reduced cash burn, the risk of funding distress remains concerning.